Veliparib (ABT888) Monotherapy for Patients with BRCA germline mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer

Trial Profile

Veliparib (ABT888) Monotherapy for Patients with BRCA germline mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2016

At a glance

  • Drugs Veliparib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Veli-BRCA
  • Most Recent Events

    • 07 Jun 2016 Results assessing efficacy of veliparib monotherapy, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Apr 2016 Status changed from active, no longer recruiting to completed as per European Clinical Trials Database record.
    • 23 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top